Patent 7157459 was granted and assigned to Taiho Pharmaceutical on January, 2007 by the United States Patent and Trademark Office.
The present invention provides an improved method for treating lung cancer, preferably non-small cell lung cancer, by orally administering UFT to postoperative lung cancer patients.